Detailed narrative
Achieving Adjusted Free Cash Flow Positive Status
Prenetics announced that its consolidated adjusted free cash flow turned positive for the first time in July 2026, a significant milestone achieved in just 20 months since the launch of IM8. This includes funding under the General Catalyst facility. The company expects Q3 FY26 to be its first positive quarter and to remain cash flow positive thereafter, attributing this success to strong customer cohorts and a $1 billion commitment from General Catalyst.
Record Q2 FY26 Performance and July Momentum
The company reported Q2 FY26 total revenue of $46.5 million, a 29% sequential increase and 3.9x growth year-over-year, marking the sixth consecutive record quarter. IM8 revenue specifically reached $45 million, up 33% sequentially with 65% gross margins. July 2026 continued this strong trend, achieving $20.9 million in revenue, an annualized run rate of $251 million, and acquiring a record 47,373 customers at a significantly reduced customer acquisition cost (CAC) of $239.
AI-Native Organization and Operational Efficiency
Prenetics highlighted its AI-native organizational structure, operating with approximately 70 employees while delivering guided revenue of $220 million to $230 million for FY26. This structure allows for higher revenue per employee and significant operating leverage, with fixed operating expenses falling 21% quarter-over-quarter despite doubling acquisition spend. AI is integrated across creative, marketing, operations, and finance, enabling compounding growth without proportional hiring.
Strategic Board Appointment and Scientific Validation
Caroline Levy, a veteran consumer analyst, joined the Prenetics Board and Audit/Governance Committees, bringing extensive experience in consumer brands and skepticism. Dr. Dawn Mussallem, a founding Scientific Advisory Board member, emphasized the company's commitment to science-backed nutraceutical solutions. She detailed three ongoing randomized placebo-controlled clinical trials, including one at the Mayo Clinic, to validate IM8 products, aiming for readouts by Q1/Q2 2027.
New Product Pipeline and Market Expansion
Prenetics plans to launch IM8 Hydration into a $37 billion market in Q4 FY26 and a premium line of gummies into a $25 billion category in Q1 FY27. These new products are expected to carry the same clinical validation and NSF certification as existing offerings. The company sees significant future growth opportunities in categories like sleep, cognition, recovery, women's health, men's health, and sports performance, leveraging its trusted brand and existing customer base.
Customer Acquisition and Retention Dynamics
The company demonstrated strong customer acquisition efficiency, with CAC improving by 21% in July 2026 compared to Q2 FY26, despite a significant increase in marketing spend. Retention rates remain high, with 14.2% retention at month 20, outperforming competitors. Over 50% of subscribers have been with the business for at least three months, indicating strong customer loyalty and product efficacy.